Catequentinib (INN; formerly anlotinib) is a pharmaceutical drug for the treatment of cancer. It is approved in China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have undergone progression or recurrence after at least two lines of systemic chemotherapy.[1] It is also approved in China as a second‑line treatment for advanced soft-tissue sarcoma.[2]

Catequentinib is a tyrosine kinase inhibitor that targets several different proteins including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.[3]

Adverse effects include hypertension, fatigue, thyroid-stimulating hormone elevation, and hand-foot syndrome, among others.[4]

References

  1. ^ Syed YY (July 2018). "Anlotinib: First Global Approval". Drugs. 78 (10): 1057–1062. doi:10.1007/s40265-018-0939-x. PMID 29943374.
  2. ^ Gao Y, Liu P, Shi R (August 2020). "Anlotinib as a molecular targeted therapy for tumors". Oncology Letters. 20 (2): 1001–1014. doi:10.3892/ol.2020.11685. PMC 7377159. PMID 32724339.
  3. ^ Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. (September 2018). "Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development". Journal of Hematology & Oncology. 11 (1): 120. doi:10.1186/s13045-018-0664-7. PMC 6146601. PMID 30231931.
  4. ^ Li S, Wang H (2023). "Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib". Drug Design, Development and Therapy. 17: 3429–3437. doi:10.2147/DDDT.S426898. PMC 10657757. PMID 38024530.
Allikas: Https://en.wikipedia.org/wiki/Catequentinib
No tags for this post.